The prediction of therapeutic targets and microRNA network in the coronavirus pathogenesis pathway

The coronavirus pathogenesis pathway is activated in coronavirus infection. To reveal the therapeutic targets of the coronavirus pathogenesis, public gene expression data were analyzed in Ingenuity Pathway Analysis (IPA). Among more than 100,000 analyses and datasets, 106 analyses and 106 datasets were related to SARS coronavirus 2. The 49 analyses were involved in SARS coronavirus 2 and human, which comprise of 27 analyses including 9 analyses on tissue "skin" GSE156754 and 22 analyses on lung adenocarcinoma. FOS and JUN in the coronavirus pathogenesis pathway were activated in SARS-CoV-2 infected lung adenocarcinoma. Coronavirus pathogenesis pathway was activated in SARS-CoV-2 infected iPS cell-derived cardiomyocytes. The molecular networks and gene expression in diffuse- and intestinal-type gastric cancer (GC) have been analyzed as well. Coronavirus pathogenesis pathway was activated in diffuse-type GC and inactivated in intestinal-type GC. Telmisartan, acetaminophen and arsenic trioxide were found to interact with the coronavirus pathogenesis pathway. NFkappaB, a target of thalidomide, was activated in diffuse-type GC. The coronavirus pathogenesis pathway had direct relationships between microRNAs including let-7, mir-10, mir-15, and mir-155. The molecules identified have potential to be the therapeutic targets.